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Background
Switch to unboosted atazanavir (ATV 400 mg qd),
although not licensed in Europe, is an attractive off-label
option due to convenience and tolerability. However
there is a substantial lack of data concerning efficacy of
ATV 400 mg-based regimens outside the trial setting.
Our aim was to perform a retrospective study of determi-
nants of long term efficacy in 2 Italian large HIV clinics.
Materials and methods
A retrospective analysis of virological (responder = last
viral load < 50 copies/ml) and PK data of patients (pts)
administered with ATV 400 mg QD + 2 N(Nt)RTIs for
at least 3 months was performed. Genotypic Sensitivity
Score (GSS) and ATV resistance associated mutations
(RAMs) were calculated according to Stanford database
using cumulative genotype. ATV Ctrough was measured
by a validated HPLC method.
Results
246 patients [65% male, mean age 47.5 years (±9), mean
BMI 23.8 Kg/m
2 (±3,4)] were considered. 40.7% and 6.6%
were HCV- or HBV-coinfected, respectively, of whom 23
(9.3% of total) were cirrhotic. 32,9% and 17.9% of pts
showed previous virological failure to NNRTIs and to PIs,
respectively. Switch to ATV was mainly (48,4%) due to
toxicity [dyslipidemia (21,5%) and gastrointestinal side
effects (9,7%)] and to simplification (28,5%); last regimen
was boosted PI-based in 178 patients (72.3%, 48% of whom
ATV/r) and NNRTI-based in 24 (9.8%). At baseline CD4+
cell count was 428 cell/mm3 (±223) and 58,1% showed
undetectable viral load. 212 (86.5%) patients had previous
genotype available: backbone GSS was < 2 in 36,9% of
patients and 6,7% had at least 1 ATV-RAM. Mean (±SD)
follow-up was 120 weeks (± 64), and 235 (95.5%) pts were
responders (74.4% still on treatment) while 11 (4.5%)
showed a virological failure (3 showed selection of ATV-
RAMs). ATV Ctrough (available in 84 patients) was higher
in responders (median value 130 vs. 70 ng/ml), although
this was not statistically significant (p>0.05). At multivari-
ate analysis, GSS<2, ATV-RAMs ≥1 and self-reported non-
adherence were associated with failure. ATV was stopped
only in 4 patients (1.6%) for side effects.
Conclusions
Over a mean follow up of more than 2 years, unboosted
ATV showed high efficacy with good tolerability even in
a clinical cohort including moderately experienced pts.
However, due to the impact of GSS of backbone and
presence of ATV-RAMs on the risk of failure, pts need
to be accurately selected. The role of ATV plasma expo-
sure deserves to be clarified on a larger sample size.
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